Higher Dietary Magnesium Intake and Higher Magnesium Status Are Associated with Lower Prevalence of Coronary Heart Disease in Patients with Type 2 Diabetes by Gant, Christina M et al.
  
 University of Groningen
Higher Dietary Magnesium Intake and Higher Magnesium Status Are Associated with Lower
Prevalence of Coronary Heart Disease in Patients with Type 2 Diabetes
Gant, Christina M; Soedamah-Muthu, Sabita S; Binnenmars, S Heleen; Bakker, Stephan J L;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Gant, C. M., Soedamah-Muthu, S. S., Binnenmars, S. H., Bakker, S. J. L., Navis, G., & Laverman, G. D.
(2018). Higher Dietary Magnesium Intake and Higher Magnesium Status Are Associated with Lower
Prevalence of Coronary Heart Disease in Patients with Type 2 Diabetes. Nutrients, 10(3), [307].
https://doi.org/10.3390/nu10030307
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Higher Dietary Magnesium Intake and Higher
Magnesium Status Are Associated with Lower
Prevalence of Coronary Heart Disease in Patients
with Type 2 Diabetes
Christina M. Gant 1,2, Sabita S. Soedamah-Muthu 3,4, S. Heleen Binnenmars 2,
Stephan J. L. Bakker 2 ID , Gerjan Navis 2 and Gozewijn D. Laverman 1,*
1 Department of Internal Medicine/Nephrology, ZGT Hospital, 7609 PP Almelo,
The Netherlands; c.gant@zgt.nl
2 Department of Internal Medicine, Division of Nephrology, University of Groningen,
University Medical Centre Groningen, 9713EZ Groningen, The Netherlands;
s.h.binnenmars@umcg.nl (S.H.B.); s.j.l.bakker@umcg.nl (S.J.L.B.); g.j.navis@umcg.nl (G.N.)
3 Centre of Research on Psychology in Somatic Diseases (CORPS), Department of Medical and Clinical
Psychology, Tilburg University, 5037 AB Tilburg, The Netherlands; S.S.Soedamah@uvt.nl
4 Institute for Food, Nutrition and Health, University of Reading, Reading RG1 5EX, UK
* Correspondence: g.laverman@zgt.nl; Tel.: +31-88-708-3079
Received: 23 January 2018; Accepted: 1 March 2018; Published: 5 March 2018
Abstract: In type 2 diabetes mellitus (T2D), the handling of magnesium is disturbed. Magnesium
deficiency may be associated with a higher risk of coronary heart disease (CHD). We investigated
the associations between (1) dietary magnesium intake; (2) 24 h urinary magnesium excretion;
and (3) plasma magnesium concentration with prevalent CHD in T2D patients. This cross-sectional
analysis was performed on baseline data from the DIAbetes and LifEstyle Cohort Twente-1 (DIALECT-1,
n = 450, age 63± 9 years, 57% men, and diabetes duration of 11 (7–18) years). Prevalence ratios (95% CI)
of CHD by sex-specific quartiles of magnesium indicators, as well as by magnesium intake per dietary
source, were determined using multivariable Cox proportional hazard models. CHD was present
in 100 (22%) subjects. Adjusted CHD prevalence ratios for the highest compared to the lowest
quartiles were 0.40 (0.20, 0.79) for magnesium intake, 0.63 (0.32, 1.26) for 24 h urinary magnesium
excretion, and 0.62 (0.32, 1.20) for plasma magnesium concentration. For every 10 mg increase of
magnesium intake from vegetables, the prevalence of CHD was, statistically non-significantly, lower
(0.75 (0.52, 1.08)). In this T2D cohort, higher magnesium intake, higher 24 h urinary magnesium
excretion, and higher plasma magnesium concentration are associated with a lower prevalence
of CHD.
Keywords: coronary heart disease; diabetes mellitus type 2; dietary magnesium intake;
urinary magnesium excretion; plasma magnesium concentration
1. Introduction
Coronary heart disease (CHD) is one of the most prevalent and high-impact complications related
to type 2 diabetes mellitus (T2D) [1,2]. In the general population, magnesium (Mg) deficiency might
be associated with a greater risk of CHD; however, data on the inverse associations between Mg status
and intake and CHD are inconsistent [3–9]. In T2D, the prevalence of hypomagnesemia is increased
14–48%, compared with 3–15% in those without T2D [10,11]. This could partly be due to increased
urinary Mg excretion caused by insulin resistance, and partly due to poor dietary Mg intake [10–13].
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However, surprisingly few studies report on the association between Mg and CHD in patients with
established T2D [14,15].
In the DIAbetes and LifEstyle Cohort Twente (DIALECT), we collected extensive data on dietary
Mg intake, 24 h urinary Mg excretion, and plasma Mg concentration. We aimed to study the association
between the parameters of Mg (i.e., dietary Mg intake, 24 h urinary Mg excretion, and serum Mg
concentration) and CHD. When we found that dietary Mg intake was inversely associated with CHD
risk, we also explored whether there was an association between Mg intake from specific dietary
sources (i.e., cereals, potatoes, etc.) and CHD risk.
2. Materials and Methods
2.1. Study Design
This was a cross-sectional analysis performed in the DIAbetes and LifEstyle Cohort Twente-1
(DIALECT-1). The study population and study procedures have been described previously [16].
The study has been approved by the relevant institutional review boards (METC-Twente, NL57219.044.16;
METC-Groningen, 1009.68020), is registered in the Netherlands Trial Register (NTR trial code 5855),
and is performed according to the guidelines of good clinical practice and the declaration of Helsinki.
2.2. Participants
All patients with T2D treated in the outpatient clinic of our hospital, aged 18+ years, were eligible
for the study. Exclusion criteria were inability to understand the informed consent procedure,
insufficient command of the Dutch language, or dialysis dependency. The inclusion flowchart has
been described previously [16]. In total, 1082 patients were eligible for the study, of which 470 agreed
to participate. The most important reasons for non-participation were no interest in the trial (n = 123),
inability due to co-morbidity (n = 62), and no transport options (n = 58). After the baseline visit,
20 patients were excluded due to the fact that their diabetes diagnosis changed from type 2 diabetes to
type 1 diabetes. Therefore, a total of 450 patients with type 2 diabetes were included in DIALECT-1.
Missing values for specific variables are listed in Table 1.
2.3. Study Procedures
Eligible patients with type 2 diabetes were selected from the electronic patient file. At the clinic,
sociodemographic characteristics, medical history, lifestyle behaviors, and current medications were
recorded and anthropometric dimension were measured. Blood pressure was measured in a supine
position by an automated device (Dinamap®; GE Medical systems, Milwaukee, WI, USA) for 15 min
with a one-minute interval. The mean systolic and diastolic pressure of the final three measurements
was used for further analysis. Physical activity was assessed using the Short QUestionnaire to ASses
Health enhancing physical activity (SQUASH) questionnaire, which was previously validated and is
commonly used in the Netherlands for population research [17].
Blood was drawn from venipuncture, for measurement of Mg and other variables relevant for
diabetes. 24 h urine collections were performed as prescribed previously [16]. Samples of blood and
urine were stored at −80 ◦C for later analysis.
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Table 1. Baseline characteristics of patients with type 2 diabetes mellitus (T2D) by a breakup of
prevalent coronary heart disease (CHD).
Total
Population No CHD CHD p-Value




Age, years 450 63 ± 9 62 ± 9 66 ± 7 <0.001
Male, n (%) 450 261 (58) 190 (54) 71 (71) 0.003
Diabetes duration, years 450 11 (7–18) 11 (7–17) 13 (7–20) 0.15
Systolic blood pressure, mmHg 449 136 ± 16 136 ± 16 136 ± 19 0.81
Diastolic blood pressure, mmHg 449 74 ± 9 75 ± 9 72 ± 10 0.01
Heart rate, beats/min 444 74 ± 13 75 ± 13 69 ± 11 <0.001
Body surface area, m2 448 2.10 ± 0.22 2.10 ± 0.23 2.07 ± 0.19 0.27
Urinary creatinine excretion, µmol/24 h 446 13.8 ± 4.8 13.8 ± 5.0 13.8 ± 4.2 0.97
Complications
Cerebrovascular disease, n (%) 450 47 (11) 87 (22) 13 (27) 0.44
Peripheral artery disease, n (%) 450 44 (10) 80 (20) 20 (44) <0.001
Retinopathy, n (%) 447 106 (24) 78 (23) 32 (32) 0.05
Neuropathy, n (%) 450 157 (36) 116 (33) 46 (46) 0.02
Diabetic nephropathy, n (%) 446 183 (42) 131 (38) 58 (58) <0.001
eGFR < 60 mL/min·1.73 m2 450 101 (23) 74 (21) 30 (30) 0.06
Microalbuminuria, n (%) 445 131 (30) 92 (27) 44 (44) 0.001
Lifestyle
Body mass index, kg/m2 448 32.8 ± 6.2 33.1 ± 6.4 32.1 ± 5.6 0.15
Body mass index ≥ 30 kg/m2, n (%) 448 290 (65) 233 (67) 57 (58) 0.12
Smoking, former or current, n (%) 450 306 (70) 235 (67) 78 (78) 0.04
Alcohol 424
No alcohol, n (%) 148 (36) 123 (37) 32 (34) 0.80
0–13 units per week, n (%) 206 (50) 159 (48) 49 (52)
≥14 units per week, n (%) 61 (15) 47 (14) 14 (15)
Adherence guideline physical activity, n (%) 433 249 (59) 201 (60) 52 (54) 0.34
Pharmacological treatment
Insulin use, n (%) 450 275 (63) 218 (62) 68 (68) 0.30
Statin use, n (%) 450 331 (76) 254 (73) 86 (86) 0.006
Beta blocker treatment, n (%) 450 202 (46) 131 (37) 77 (77) <0.001
RAAS inhibition, n (%) 450 289 (66) 225 (64) 73 (73) 0.10
Calcium antagonists, n (%) 450 98 (22) 66 (19) 36 (36) <0.001
Thiazide diuretics, n (%) 450 136 (31) 108 (31) 29 (29) 0.72
Loop diuretics, n (%) 450 75 (17) 48 (14) 33 (33) <0.001
Number of antihypertensives 450 2 (1–3) 2 (1–3) 3 (2–4) <0.001
Magnesium parameters
Dietary magnesium intake *, mg/day 438 305 ± 46 309 ± 47 292 ± 40 0.001
Urinary magnesium excretion, mmol/24 h 402 3.94 ± 2.05 4.03 ± 2.05 3.66 ± 2.02 0.13
Plasma magnesium concentration, mmol/L 432 0.77 ± 0.09 0.78 ± 0.08 0.76 ± 0.09 0.06
Hypomagnesemia, n (%) 432 73 (17) 53 (16) 20 (20) 0.35
Serum values
Total cholesterol, mmol/L 447 4.0 ± 0.9 4.1 ± 0.9 3.8 ± 1.1 0.04
HDL cholesterol, mmol/L 445 1.1 ± 0.3 1.2 ± 0.4 1.0 ± 0.3 <0.001
LDL cholesterol, mmol/L 428 2.0 ± 0.7 2.0 ± 0.7 1.9 ± 0.8 0.25
HbA1c, mmol/mol 448 57 ± 12 57 ± 12 58 ± 12 0.43
Dietary intake
Total energy intake, kcal/day 438 1922 ± 629 1904 ± 649 1932 ± 630 0.71
Urinary sodium excretion, mmol/24 h 444 185 ± 79 183 ± 67 197 ± 84 0.14
Urinary potassium excretion, mmol/24 h 439 77 ± 25 78 ± 26 77 ± 21 0.87
Calcium intake, mg/day 438 969 ± 441 979 ± 467 905 ± 358 0.16
Fiber intake, g/day 438 20.9 ± 6.6 20.8 ± 7.0 20.4 ± 6.1 0.60
Cholesterol, g/day 438 194 ± 96 195 ± 101 188 ± 79 0.51
Total fat intake, g/day 438 79 ± 39 78 ± 34 81 ± 34 0.52
Total protein intake, g/day 438 79 ± 23 79 ± 24 76 ± 22 0.18
Total carbohydrate intake, g/day 438 207 ± 69 205 ± 72 209 ± 67 0.61
CHD: coronary heart disease, eGFR: estimated glomerular filtration rate (CKD-EPI), HDL: high density lipoprotein,
LDL: low density lipoprotein, HbA1c: glycated hemoglobin. * Dietary magnesium intake was adjusted for total
energy intake using the residual method.
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2.4. Magnesium Measurements
We calculated dietary Mg intake using a semi-quantitative food frequency questionnaire (FFQ),
inquiring about the intake of 177 items during the last month, taking seasonal variations into
account [18]. The FFQ was developed and validated at the Wageningen University, and has been
updated several times. For each food item, the frequency was recorded in times per day, week,
or month. The number of servings was expressed in natural units (e.g., a slice of bread or a whole
apple) or household measures (e.g., cup or spoon). Both questionnaires were self-administered and
filled in at home. The filled-in questionnaires were checked for completeness by a trained researcher,
and inconsistent answers were verified with the patients. If the patient could not remember an exact
number, the trained researcher approximated the intake as closely as possible during the interview.
Dietary data was converted into daily nutrient intake using the Dutch Food Composition Table of
2013 [19]. We calculated the average intake of Mg by multiplying the frequency of consumption of
each food item by its Mg content in the Dutch Food Composition Table of 2013 [19], and summing
the amount of Mg across all food items. We calculated Mg intake from different food categories by
multiplying the frequency of consumption of each food item in that specific category by its Mg content,
and summing across all food items in that category. Food items of the FFQ included in each category
are listed in supplementary Table S1.
Plasma and urinary Mg were measured in stored plasma samples in routine laboratory
measurements using the xylidyl blue method. Buffer/Ethylenediaminetetraacetic acid was added
to mask calcium. After incubation, xylidyl blue was added to form a purple complex with Mg.
Mg concentration was determined by the photometric measurement of xylidyl blue extinction.
The detection range for plasma Mg was 0.1–5 mmol/L, and for 24 h urinary Mg the range was
0.5–25 mmol/L. There were no patients with values outside of the detection ranges. Hypomagnesemia
was defined as serum Mg concentration <0.70 mmol/L.
2.5. Main Study Outcome
Coronary heart disease (CHD) is defined as physician-diagnosed unstable angina pectoris or
myocardial infarction, percutaneous coronary intervention, or a coronary artery bypass graft in the
medical history. Medical history was checked for CHD during the interview at the baseline visit,
and was later reviewed in the hospital electronic patient files on three different occasions, by three
different physician researchers, who were unware of the magnesium data.
2.6. Statistics
All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS),
version 23.0. Normally-distributed data are presented as mean± standard deviation. Skewed variables
are expressed as median (interquartile range). Dichotomous variables are presented in number and
percentage. Dietary intake of Mg was adjusted for energy intake by the residual method [20].
Differences between T2D patients with and without CHD were determined using the Student t
(normal distribution), Mann–Whitney U (skewed distribution), or Chi-Square (categorical variables)
test. In order to examine parameters associated with magnesium intake, we divided the population into
sex-specific quartiles of adjusted magnesium intake. Differences between the quartiles were assessed
using one-way ANOVA (normal distribution), Kruskal–Wallis (skewed distribution), or Chi-Square
(categorical variables) analysis.
Correlations between Mg parameters were assessed using Pearson’s correlation coefficient.
We calculated the prevalence ratio (95% CI) of CHD by sex-specific quartiles of (1) dietary Mg
intake; (2) 24 h urinary Mg excretion; and (3) plasma Mg concentration, using multivariable Cox
proportional hazard models, with the time to event set at 1 for all patients. The models were adjusted
for the potential confounding of lifestyle parameters (BMI, smoking, alcohol, and physical activity)
and nutritional intake (24 h urinary sodium excretion and 24 h urinary potassium excretion) [3,21].
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There was a strong correlation between dietary calcium and Mg intake (R = 0.70), therefore we did
not adjust for calcium intake in the final model. Effect modification was checked for gender, BMI,
smoking, and alcohol, and no significant effect modification was found (p > 0.20 for all interaction
terms). Sensitivity analyses were performed by excluding patients with diabetic kidney disease,
and prevalence ratios were similar as in the primary analyses.
Additionally, we performed multivariable Cox proportional hazard models, and calculated the
prevalence ratios of CHD for each 10 mg increment of dietary Mg intake from different sources
(cereals, dairy, coffee, potatoes, meat, legumes and nuts, fruit, vegetables, and other). The models were
adjusted for potential confounding of lifestyle parameters (age, BMI, smoking, alcohol, and physical
activity) and Mg intake from the miscellaneous sources.
3. Results
In total, 450 patients with T2D were included in DIALECT-1. Baseline characteristics are shown
in Table 1. In short, patients were 63 ± 9 years old, and the majority of the population was male (57%).
The population represents T2D in secondary health care, with a median diabetes duration of 11 (7–18)
years, and a high prevalence of diabetic nephropathy (42%).
There were 100 (22%) CHD cases diagnosed in our population (Table 1). T2D patients with CHD
were older (66 ± 7 vs. 62 ± 9 years, p < 0.001), were more often men (71% vs. 54%, p = 0.003), and more
often had peripheral artery disease (44% vs. 20%, p < 0.001), and nephropathy (58% vs. 38%, p < 0.001)
than patients without CHD. There were no differences in lifestyle parameters between those with and
without CHD. Regarding pharmacological treatment, those with CHD more often used beta-blockers
(77% vs. 37%, p < 0.001), and loop diuretics (33% vs. 14%, p < 0.001) than those without CHD. This was
paralleled by a lower diastolic blood pressure (72 ± 10 mmHg vs. 75 ± 9 mmHg, p = 0.01) and heart
rate (69± 11 beats/min vs. 75± 13 beats/min, p < 0.001) in patients with CHD. Systolic blood pressure
was 136 ± 16 mmHg, and did not differ between the groups. Although patients with CHD more
often used statins (86% vs. 73%, p = 0.006), serum LDL was similar in the groups (2.0 ± 0.7 mmol/L),
and serum HDL cholesterol was lower in those with CHD (1.0 ± 0.3 mmol/L vs. 1.2 ± 0.4 mmol/L,
p < 0.001) compared to those without CHD.
Mean energy-adjusted dietary Mg intake was 305 ± 46 mg/day, and was lower in those
with CHD (adjusted standardized beta = −0.14, p = 0.003). Mean 24 h urinary Mg excretion was
3.94 ± 2.05 mmol/24 h, and mean plasma Mg concentration was 0.77 ± 0.09 mmol/L; neither
differed statistically significantly between those with and without CHD (Table 1). Hypomagnesemia
(plasma Mg < 0.7 mmol/L) was present in 73 patients (17%), of which 11 patients (3%) had a plasma
Mg of <0.6 mmol/L.
Dietary Mg intake was significantly correlated with 24 h urinary Mg excretion (Pearson R = 0.24,
p < 0.001), but not with plasma Mg (R = 0.02, p = 0.64). 24 h urinary Mg excretion was significantly
correlated with plasma Mg (R = 0.13, p < 0.008).
Systolic blood pressure was lowest in the highest gender-specific quartile of energy-adjusted
magnesium intake (4th quartile 133 ± 13 vs. 1st quartile 137 ± 17 mmHg; Supplementary Table S2),
and the number of antihypertensive drugs used was lowest in this quartile as well (4th quartile 2 (0–3)
vs. 2 (1–3) in other quartiles, p = 0.008). Serum HbA1c and cholesterol levels were similar in all Mg
intake quartiles. There was a trend towards higher urinary potassium excretion, dietary calcium, fiber,
protein, and carbohydrate intake, as well as a lower dietary intake of fat in each of the higher quartiles
of magnesium intake.
3.1. Association between Dietary Magnesium Intake, 24 h Urinary Magnesium Excretion, Plasma Magnesium
Concentration, and the Prevalence of Coronary Heart Disease
The highest quartile of Mg intake was significantly associated with a lower prevalence ratio (PR)
of CHD than the lowest quartile of Mg intake (0.40 (0.20, 0.77); Table 2). When adjusting for age and
lifestyle parameters (BMI, smoking, alcohol, and physical activity), the PR remained largely unchanged
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(0.42 (0.22, 0.82)). After adjustment for dietary intake of other micronutrients (total energy intake,
sodium, and potassium), the PR became (0.40 (0.20, 0.79)), and the p-trend was 0.01.
There was a similar trend towards a lower prevalence of CHD in the highest quartile of 24 h
urinary Mg excretion, which was not statistically significant (PR 0.63 (0.33, 1.19)). After adjustment for
lifestyle and nutritional factors, the PR remained similar (0.63 (0.32, 1.26)). Also, the highest quartile of
plasma Mg concentration had a non-significant trend towards a lower prevalence of CHD (unadjusted
PR 0.60 (0.31, 1.14), adjusted PR 0.62 (0.32, 1.20)). The PR ratios for dietary Mg intake, urinary Mg
excretion and plasma Mg concentration did not change after further adjustment for other classic CHD
risk factors, namely systolic blood pressure and LDL cholesterol (data not shown).
Table 2. Prevalence ratios (95% CI) for associations between dietary, urinary and plasma Magnesium
and coronary heart disease in type 2 diabetes from the DIAbetes and LifEstyle Cohort Twente
(DIALECT) (n = 450).
Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-Trend
Dietary Mg intake *, mg/day 254 ± 25 291 ± 7 315 ± 8 361 ± 39
n cases/n total 33/109 25/110 23/110 13/109
Model 1 a 1.00 0.71 (0.42, 1.22) 0.64 (0.37, 1.10) 0.40 (0.20, 0.77) 0.005
Model 2 b 1.00 0.72 (0.42, 1.23) 0.69 (0.40, 1.21) 0.42 (0.22, 0.82) 0.01
Model 3 c 1.00 0.71 (0.41, 1.23) 0.72 (0.41, 1.27) 0.40 (0.20, 0.79) 0.01
Urinary Mg excretion, mmol/24 h 1.81 ± 0.63 3.05 ± 0.32 4.32 ± 0.57 6.64 ± 1.75
n cases/n total 24/101 24/100 19/101 15/100
Model 1 a 1.00 0.95 (0.54, 1.67) 0.73 (0.39, 1.35) 0.63 (0.33, 1.19) 0.24
Model 2 b 1.00 1.28 (0.71, 2.30) 0.96 (0.51, 1.82) 0.74 (0.39, 1.42) 0.33
Model 3 c 1.00 1.27 (0.70, 2.30) 0.85 (0.44, 1.65) 0.63 (0.32, 1.26) 0.13
Plasma Mg concentration, mmol/L 0.67 ± 0.06 0.75 ± 0.02 0.80 ± 0.02 0.88 ± 0.04
n cases/n total 29/113 22/106 27/111 16/102
Model 1 a 1.00 0.91 (0.52, 1.60) 1.03 (0.60, 1.77) 0.60 (0.31, 1.14) 0.15
Model 2 b 1.00 0.91 (0.51, 1.62) 1.09 (0.63, 1.89) 0.58 (0.30, 1.12) 0.17
Model 3 c 1.00 0.91 (0.51, 1.63) 1.12 (0.65, 1.94) 0.62 (0.32, 1.20) 0.26
a Model 1: Crude model b Model 2: Adjusted for age (years), BMI (kg/m2), smoking (never, former or current),
alcohol consumption (none, 1–13 units per week, ≥14 units per week), physical activity (not adherent to guideline,
adherent to guideline).c Model 3: Model 2 + Total energy intake (kcal), 24 h urinary sodium excretion (mmol/24 h)
and 24 h urinary potassium excretion (mmol/24 h).* Dietary magnesium intake was adjusted for total energy intake
using the residual method.
3.2. Analysis on Source of Magnesium Intake and Prevalence of CHD
We performed an explorative analysis whether there was an association between Mg intake from
specific dietary sources and CHD. The largest dietary contributors to total dietary Mg intake for patients
with T2D (Figure 1) were cereals at 22% (16–26%), dairy at 14% (10–20%), coffee at 9% (6–13%), potatoes
at 7% (4–10%), meat at 6% (5–8%), legumes and nuts at 6% (4–11%), fruit at 5% (3–8%), and vegetables
with 3% (2–5%). We found no statistically significant association between Mg intake from specific food
groups and CHD (Table 3). However, there was a non-significant trend towards a lower prevalence of
CHD for every 10 mg increase of dietary Mg intake derived from vegetables (PR 0.75 (0.52, 1.08)).
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Magnesium intake from fruit *, 10 mg/day 1.00 (0.81, 1.23) 0.98 (0.79, 1.20) 0.96 (0.78, 1.19)
Magnesium intake from vegetables *, 10 mg/day 0.71 (0.51, 1.01) 0.71 (0.50, 1.01) 0.75 (0.52, 1.08)
Magnesium intake from miscellaneous sources *, 10 mg/day 0.95 (0.89, 1.02) 0.95 (0.89, 1.03) 0.90 (0.82, 0.99)
a Model 1: Crude model b Model 2: Adjusted for age (years), BMI (kg/m2), smoking (never, former/current), alcohol
consumption (none, 1–13 units per week, ≥14 units per week), physical activity (not adherent to guidelin , adherent
to guideline).c Model 3: Model 2 + Total energy intake (kcal), magnesium intake from the other sources (cereals
(mg/day), dairy (mg/day), coffee (mg/day), potatoes (mg/day), meat (mg/day), legumes and nuts (mg/day),
fruit (mg/day), vegetables (mg/day), and other (mg/day)). * Magnesium intake from food sources was adjusted
for total energy intake using the residual method. An increment of 10 mg magnesium intake per day was used to
calculate PR.PR, prevalence ratio; CI, confidence interval.
4. Discussion
We found inverse associations for dietary Mg intake, 24 h urinary Mg excretion, and plasma Mg
concentration with the prevalence of CHD in patients with T2D. As far as we know, this is the first
study in T2D patients which simultaneously reports on these three Mg parameters in relation to CHD.
The inverse association between dietary Mg intake and the prevalence of CHD we found was strongest
for Mg intake derived from vegetables, albeit not statistically significant.
The mean dietary Mg intake we report (305 ± 46 mg/day) w s somewha lower than the median
Mg intake in the general Dutch population, which is around 350 g/d y [22], but was comparable
to median Mg intake of population studies in the U.S. (308 mg/day) [4]. We found that in the Dutch
population, cereals, dairy, and coffee intake were the largest contributors to total Mg intake, at 22%,
14%, and 9% respectively. This was somewhat different from the U.K. population, where cereals (34%),
meat (19%), and dairy (18%) intake were the most important contributors [23]. In contrast, in the U.S.
population the most mportant food groups were vegetabl s (13%), milk (8%), meat (7%) [24].
It should be noted that different groupings of food products renders a head-to-head comparison
between these percentages difficult. The 24 h urinary Mg excretion we report (4.0 ± 2.1 mmol/24 h)
was in line with the general population the Netherlands (4.2 ± 1.7 mmol/24 h for men and
3.5 ± 1.4 mmol/24 h for women) [5]. Plasma Mg concentration (0.77 ± 0.09 mmol/L) was similar
to an earlier report about Dutch diabetes patients (0.74 ± 0.10 mmol/L) [25]. The prevalence of
hypomagnesemia we found (17%) was in the range of the reported prevalence of hypomagnesemia
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in patients with T2D, between 14% and 48% [10,11], and emphasizes that clinical vigilance for
hypomagnesemia is warranted in T2D, because it is associated with increased insulin resistance
and faster renal function decline [26].
We are the first to report an inverse association between dietary Mg intake and the prevalence
of CHD in T2D. In contrast, a large meta-analysis in non-T2D patients demonstrated no association
between dietary Mg intake and incident CHD [9]. However, low dietary Mg intake was associated with
a higher risk of stroke, heart failure, new-onset diabetes, and all-cause mortality [9]. It is known that in
T2D renal wasting of Mg occurs [27]. Additionally, Mg supplementation in T2D can improve insulin
sensitivity and metabolic control [28]. Possibly, an adequate Mg intake in patients with T2D is even
more important than in those without T2D, in order to maintain an adequate Mg status and prevent
diabetes-related complications. These data fuel the hypothesis that magnesium intake is beneficial in
T2D patients.
In addition, when investigating Mg intake from specific food sources, we found the strongest
inverse association between Mg derived from vegetables and CHD, albeit not quite reaching statistical
significance. To our knowledge, the association with vegetable-derived Mg intake and CHD has
not been described before. When studying Mg intake and Mg status, it is important to consider
bioavailability of ingested Mg for intestinal uptake, as this might vary considerably depending on
the source of Mg intake [29]. Possibly, bioavailability from Mg in vegetables is greater than from
other food sources; however, this issue would have to be addressed an in-depth mechanistic study.
Nevertheless, our data illustrate that when studying the association between micronutrients and
outcomes, intake of different food groups is also important. As vegetable intake in our population was
low [30], and vegetable intake only accounted for 3% of total Mg intake in this population, increasing
vegetable intake is a good opportunity to not only increase Mg intake, but also to improve overall diet
quality. It should be noted that in our study, it is difficult to distinguish between the protective effects
of overall vegetable intake and those from vegetable-derived Mg intake. Other vegetable-derived
components like antioxidants, but also potassium and vitamin K, might contribute to or interact
with Mg in the eventual association with CHD [31–34]. Maybe the possible cohort effect from these
micronutrients and Mg could amplify such protection. Since such an analysis is beyond the scope and
available data of the current study, future studies are necessary to further investigate mechanisms
behind vegetable intake and risk of coronary heart disease.
Additionally, we found that lower 24 h urinary Mg excretion was associated with more prevalent
CHD. In line with this finding, in the general population an inverse association between Mg excretion
and CHD was reported [5]. Potential renal Mg wasting in T2D renders the interpretation of urinary
Mg excretion difficult. High urinary Mg excretion could, on the one hand, reflect a high dietary
Mg intake; on the other hand, though, it could reflect the hypermagnesuria found in T2D [10,11].
This could explain why, in our cohort, dietary Mg intake is more strongly associated with CHD than
24 h urinary excretion.
In parallel, lower plasma Mg concentration was also associated with prevalent CHD. In T2D,
the association between plasma Mg concentration and CHD was investigated previously, and conflicting
results were reported [14,15]. In non-T2D subjects, conflicting results on the association between plasma
Mg have been reported as well; however, a meta-analysis demonstrated an inverse association between
plasma Mg and incident CHD [8]. As Mg is mainly an intracellular cation, and therefore plasma Mg
only reflects 1% of bodily Mg stores, the validity of using plasma Mg as a marker for Mg status has
been questioned; Mg deficiency has been reported in patients without overt hypomagnesemia [11,35].
Our paper was not designed to unravel mechanisms behind the inverse associations between Mg
intake, Mg status, and CHD. However, several mechanisms have been proposed that could underlie
this association. First, animal studies have consistently shown that higher Mg status inhibits vascular
calcification [36,37]. In human subjects, serum Mg and dietary Mg intake were inversely associated
with the degree of coronary calcification [4,6]. Second, low Mg status might be associated with cardiac
arrhythmias [38]. Lastly, increased CHD risk might be mediated through the association between low
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Mg status or intake and increased traditional CHD risk factors, such as blood pressure [39] and insulin
resistance [12].
Our paper is the first to simultaneously report the association between dietary Mg intake, factors
of Mg status (24 h urinary Mg excretion and plasma Mg), and CHD in patients with established
T2D. The robustness of our findings is established through the fact that all three Mg parameters
were inversely associated with CHD. The main limitation of our paper is the cross-sectional design,
which only allowed us to study associations and not causality, and therefore there is a risk of reverse
causality bias. Another limitation is that the FFQ we used in our study was not validated to estimate
magnesium intake. However, because there was a moderate correlation between dietary Mg intake
and urinary Mg excretion, we deemed the results sufficiently valid.
Our study has several clinical implications. First, we show that Mg intake is of the utmost
importance with relation to T2D. Patients with T2D are at risk of developing hypomagnesemia, as Mg
intake in our population was somewhat lower in comparison to the general population. Additionally,
patients with T2D have increased renal Mg excretion [27]. We show that Mg intake and Mg status is
reduced in those with CHD, possibly indicating that higher Mg intake is associated with a lower risk
of CHD. The best opportunity to increase Mg intake is to increase intake of Mg-rich vegetables. As Mg
intake in the highest quartile is approximately 100 mg/day higher than in the lowest quartile, in clinical
practice this could correspond with increasing vegetable intake by, for example, 200 g spinach, or 100 g
rucola lettuce and two avocados per day. Alternatively, previous research has shown that several
dietary patterns might reduce CHD risk or improve cardiac function, such as the Mediterranean diet;
the Dietary Approaches to Stop Hypertension diet; or a high-protein, intermittent fasting, low-calorie
diet [40–42]. We add to these findings by illustrating that Mg is an important component in such
diets. For future studies, it would be of interest to investigate how Mg and other beneficial nutritional
approaches could reinforce each other in the pursuit of the reduction of CHD in diabetes patients.
Additionally, future mechanistic studies should be done to investigate how vegetable-derived nutrients,
particularly Mg, might reduce CHD risk.
5. Conclusions
In a cohort of patients with established T2D, dietary magnesium intake, 24 h urinary magnesium
excretion, and plasma magnesium concentration were inversely associated with the prevalence of
coronary heart disease. Increasing dietary magnesium intake, especially through increasing vegetable
intake, may reduce the risk of CHD in patients with established T2D.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/10/3/307/s1,
Table S1: Overview of food items included in each food category, Table S2: Baseline characteristics of patients
with T2D by a breakup of dietary magnesium intake.
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